About Us

NEX-I, First-In-Class Cancer Immunotherapy Development Company



Improving quality of life through treatment

NEX-I develops innovative treatments to improve the quality of life for patients and their family.


Providing new clinical values

NEX-I drives a paradigm shift from the current regime of standard of care in anti-cancer therapies to provide new clinical values.


Platform and assessment tool development by design

Through next-generation discovery platform, NEX-I designs assessment tools for the target efficacy of First-In-Class cancer immunotherapy.